NASDAQ:RPRX • GB00BMVP7Y09
Past quarterly earnings results for ROYALTY PHARMA PLC- CL A (RPRX), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Actual vs estimated values, surprises, q2q growth and acceleration numbers for recent quarters.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | 1.47 | 1.35 | 8.69% | 27.83% | 621.99M | 811.83M | -23.38% | 4.71% |
| Q3 2025 | 1.17 | 1.06 | 9.99% | 15.84% | 814M | 754.04M | 7.95% | 44.07% |
| Q2 2025 | 1.14 | 1.11 | 3.01% | 18.75% | 727M | 697.73M | 4.20% | 19.57% |
| Q1 2025 | 0.65 | 1.62 | -59.90% | -33.67% | 839M | 765.47M | 9.61% | 47.71% |
| Q4 2024 | 1.15 | 1.08 | 6.88% | - | 594M | 692.47M | -14.22% | -0.34% |
| Q3 2024 | 1.01 | 0.95 | 6.65% | 27.85% | 565M | 710.02M | -20.42% | 5.35% |
| Q2 2024 | 0.96 | 0.98 | -2.47% | 14.29% | 608M | 641.1M | -5.16% | 13.01% |
| Q1 2024 | 0.98 | 1.00 | -2.16% | -38.75% | 568M | 676.48M | -16.04% | -16.96% |
| Q4 2023 | 1.15 | 1.03 | 11.63% | -26.28% | 596M | 705.48M | -15.52% | 5.36% |
| Q3 2023 | 0.79 | 0.77 | 2.45% | 9.72% | 536.313M | 630.35M | -14.92% | -6.48% |
| Q2 2023 | 0.84 | 0.82 | 1.92% | 6.33% | 538M | 547.32M | -1.70% | 0.37% |
| Q1 2023 | 1.60 | 1.30 | 23.19% | 166.67% | 684M | 869.96M | -21.38% | 21.71% |
| Q4 2022 | 1.56 | 1.50 | 3.86% | 95.00% | 565.7M | 970.32M | -41.70% | -1.74% |
| Q3 2022 | 0.72 | 0.73 | -1.45% | 323.53% | 573.5M | 598.92M | -4.24% | -2.10% |
| Q2 2022 | 0.79 | 0.80 | -0.86% | -26.85% | 536M | 553.02M | -3.08% | -3.42% |
| Q1 2022 | 0.60 | 0.75 | -19.60% | 233.33% | 562M | 611.75M | -8.13% | -1.92% |
| Q4 2021 | 0.80 | 0.79 | 1.20% | 185.71% | 575.7M | 567.42M | 1.46% | 0.63% |
| Q3 2021 | 0.17 | 0.71 | -75.92% | -64.58% | 585.8M | 584.26M | 0.26% | 8.80% |
| Q2 2021 | 1.08 | 0.71 | 52.35% | 47.95% | 555M | 528.25M | 5.06% | 8.63% |
| Q1 2021 | 0.18 | 0.66 | -72.85% | - | 573M | 519.89M | 10.22% | 14.39% |
| Q4 2020 | 0.28 | 0.71 | -60.46% | - | 572.1M | 490.33M | 16.68% | - |
| Q3 2020 | 0.48 | 0.60 | -20.46% | - | 538.4M | 462.23M | 16.48% | - |
| Q2 2020 | 0.73 | 0.62 | 17.60% | - | 510.9M | 478.34M | 6.81% | - |
| Q1 2020 | - | - | 500.9M | - | - |
Notes
ROYALTY PHARMA PLC- CL A (RPRX) last reported earnings on 2/11/2026.
ROYALTY PHARMA PLC- CL A (RPRX) beat EPS estimates and missed revenue estimates in the most recent quarter.
In the last 4 quarters, ROYALTY PHARMA PLC- CL A (RPRX) has beaten EPS estimates in 3 out of 4 releases.